News and Media

Quantum Genomics announces the appointment of international experts as members of its Scientific Advisory Board

27 October 2014
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the three other members of its Scientific Advisory Board Committee headed by Professor Pierre Corvol who was appointed on July 8, 2014 […]

Quantum Genomics receives financial aid from Bpifrance (France Public Innovation Bank) for its research program evaluating combinations of its new class of molecules with other anti-hypertensive compounds

3 September 2014
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it received a 260 K€ subsidized financing from Bpifrance for its research program assessing combinations of BAPAIs (Brain Aminopeptidase A Inhibitors) with […]

Professor Pierre Corvol appointed Chairman of the Scientific Advisory Board of Quantum Genomics

8 July 2014
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the appointment of Professor Pierre Corvol as Chairman of its Scientific Advisory Board […]

Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece)

18 June 2014
|

Quantum Genomics, (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, in scientific collaboration with Dr. Catherine Llorens-Cortes (INSERM U1050/Collège de France), presented during the Congress HYPERTENSION 2014, held in Athens […]